Floatz logo

FAPi-46

Malignant Testicular Neoplasm

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Malignant Testicular Neoplasm cohort.

Asset / SponsorPhaseRating
TESTOSTERONE UNDECYLATE
University Medical Center Groningen
Phase 2/3BB
Etarfolatide
Endocyte
Phase 2B
FLUOROURACILUM
National Cancer Institute (NCI)
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B
Flavopiridol
National Cancer Institute (NCI)
Phase 2B

View all 20 →

Same molecule, other indications

FAPi-46 is also rated in:

cholangiocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
melanomaDormant
CCC
Indicative ·
53 / 100
View asset →
amyloidosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →